Overview

A Multicenter, Randomized, Double-blind, Withdrawal Trial Assessing the Efficacy, Safety, and Tolerability of AVTX-801 in Subjects With PGM1-CDG

Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, withdrawal study assessing the efficacy, safety, and tolerability of AVTX-801 in subjects with PGM1-CDG.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Eva Morava-Kozicz